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Abstract: Shock in cardio-surgical intensive care unit (ICU) patients requires prompt identification of
the underlying condition and timely therapeutic interventions. Management during the first 6 hours, also
referred to as “the golden hours”, is of paramount importance to reverse the shock state and improve
the patient’s outcome. The authors have previously described a state-of-the-art diagnostic work-up and
discussed how to optimise preload, vascular tone, contractility, heart rate and oxygen delivery during
this phase. Ideally, shock can be reversed during this initial period. However, some patients might
have developed multiple organ dysfunction, which persists beyond the first 6 hours despite the early
haemodynamic treatment goals having been accomplished. This period, also referred to as “the silver
days”, is the focus of this review. The authors discuss how to reduce vasopressor load and how to
minimise adrenergic stress by using alternative inotropes, extracorporeal life-support and short acting
beta-blockers. The review incorporates data on fluid weaning, safe ventilation, daily interruption of
sedation, delirium management and early rehabilitation. It includes practical recommendations in areas
where the evidence is scarce or controversial. Although the focus is on cardio-surgery ICU patients, most
of the considerations apply to critical ill patients in general.
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Acute Heart Failure
Shock in cardio-surgical intensive care unit (ICU) patients is a serious 
condition associated with a high morbidity and mortality.1,2 Prompt 
identification of the underlying condition and timely therapeutic 
interventions are key to reverse the shock state and to improve 
the patients’ outcome. Hence, the management during the first 
6 hours is of paramount importance. This time period is also referred to 
as “the golden hours”. Ideally, a correct diagnosis is established allowing 
specific treatments. The authors have previously described a state-of-
the-art diagnostic work-up and discussed how to optimise preload, 
vascular tone, contractility, heart rate and oxygen delivery during this 
phase.3 Ideally, shock can be reversed during this initial period, however 
some patients might have developed multiple organ dysfunction that 
persists beyond the first 6 hours despite the early haemodynamic 
treatment goals been accomplished.4 This period, also referred to as 
“the silver days”, is the focus of this review. The authors discuss the 
management of organ dysfunction in critically ill patients after cardiac 
surgery. The following recommendations (summarised in Table 1) are 
not exclusive, rather they highlight some important considerations to be 
made while treating these patients after the initial resuscitation phase.
Methods
For this narrative review, a search of the PubMed database and a review 
of bibliographies from selected articles were performed to identify 
original data relating to this topic. Key words used for the search 
were, among others, “haemodynamic management” “vasopressors”, 
“levosimendan”, inotropes”, inotropic therapy”, “nutrition”, “sedation”, 
“ventilation”, “weaning from mechanical ventilation”, “delirium” and 
“procalcitonin”. National and international guidelines were reviewed 
and integrated, e.g. the “Guidelines for the Diagnosis and Treatment of 
Acute and Chronic Heart Failure” of the European Society of Cardiology 
(ESC)5 and the “Consensus on circulatory shock and haemodynamic 
monitoring“ from the Task force of the Society of Intensive Care 
Medicine (ESICM).6
Articles were scrutinised regarding their study design, population 
evaluated, interventions, outcomes and limitations. Finally, personal 
recommendations were included and highlighted as such to give a 
comprehensive overview on this topic.
Optimise Haemodynamics 
Reduce Vasopressor Load
The optimal mean arterial blood pressure (MAP) under vasopressor 
therapy is still under investigation. For patients with septic shock, no 
benefit was found after increasing the MAP by use of vasopressors 
above 65–70  mmHg.7 Moreover, higher vasopressor loads were 
associated with higher mortality.8 However Asfar et al. showed that 
targeting a MAP of 80–85 mmHg in patients with chronic arterial 
hypertension reduced the incidence of renal replacement therapy.7 
Therefore, the authors follow the recommendations of the 2014 
consensus report of the ESICM6 and target an individualised blood 
pressure rather than fixed MAP-goals after the first phase of life-
saving measures. In patients that remain anuric despite a MAP of 
70  mmHg, the blood pressure target is reduced. In patients with 
critical vascular stenosis or right heart failure, the MAP is not reduced 
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Table 1: Summary of Recommendations During Shock Management for Cardio-surgical Intensive Care Unit Patient (The Silver Days)





•   Consider a reduction of the MAP goal.  
•   Consider levosimendan in patients with impaired cardiac contractility. 
•   Consider extracorporeal life support as bridge to recovery, bridge to transplant or bridge to destination in prolonged states of  
     shock and patients with increased risk of hypoperfusion.  
•   Treat non-compensatory tachycardia with esmolol, aim for a heart rate between 80 to 95 BPM.
Renal replacement therapy •   CVVHD in patients with fluid overload not responding to diuretics, metabolic acidosis (pH <7.2) or potassium levels >6.0 mmol/l.
Lung-protective ventilation 
 
•   Select tidal volume of 6 ml/kg ideal body weight. 
•   Limit plateau pressure to < 30 mbar. 




•   Start enteral nutrition with 5 kcal/kg when shock resolves. 
•   Increase daily caloric intake to 25 kcal/kg ideal body within 4 days. 
•   Consider parenteral nutrition from day four if caloric intake is <60 % of target and increase supplementation stepwise to 
     80 % of target.




•   Use light sedation, define RASS target. 
•   Prefer short acting sedatives. 
•   Interrupt sedation daily if long-acting sedatives are used. 
•   Identify and treat delirium.
Reassess antibiotic  
treatment
•   Switch to more specific treatment. 
•   Consider termination of an empirical antibiotic therapy, if no organism is identified and shock has resolved.
BPM = beats per minute; CVVHD = continuous veno-venous haemodyalisis; MAP = mean arterial pressure; PEEP = positive end-exspiratory pressure; RASS = Richmond Agitation–Sedation Scale 
<65 mmHg. In all others, MAP targets are continuously reduced and 
sometimes tolerated as low as 50 mmHg in order to reduce the 
amount of vasopressors necessary. 
Consider Alternative Inotropes
Beta-adrenergic drugs have been associated with considerable risks 
including adverse effects on metabolism, bacterial growth and alterations 
of the innate immune response.9–13 Also, the amount and duration of 
catecholamines is independently associated with adverse cardiac events 
such as tachyarrhythmia and prolonged elevated heart rate.14 Hence, 
efforts are necessary to limit the use of these drugs as much as possible. 
One alternative is the inodilator levosimendan. It increases the troponin 
C affinity for Ca2+, which results in strengthening of the myocardial 
contraction without increasing oxygen demand.15 Also, it has vasodilator-
properties via activation of ATP-dependent potassium channels.16 The 
use of Levosimendan in cardiogenic shock is controversial because 
patients with cardiogenic shock have been excluded in safety studies as 
levosimendan causes vasodilation.17 It is recommended by the 2013 ESC 
guidelines on heart failure in cardiogenic shock and second line treatment 
for low output heart failure if the effect of beta blockage is thought to 
be the reason for hypoperfusion.5 The Levosimendan Infusion versus 
Dobutamine (LIDO) study showed a survival benefit of levosimendan after 
6 months.16,18 The Survival Of Patients With Acute Heart Failure In Need 
Of Intravenous Inotropic Support (SURVIVE) study found an advantage 
in patients with decompensated chronic heart failure previously treated 
with beta blockers.17,19,20 Another study showed the combination of 
levosimendan and dobutamine to be more effective compared to 
dobutamine alone.21 In cardiac surgery, levosimendan has shown to 
produce a dose dependent effect on stroke volume, also when given 
preoperatively in patient at risk, and to shorten length of ICU stay.22 It is the 
only inotrope which might decrease the mortality after cardiac surgery.23 
The authors use levosimendan for persisting heart failure after shock 
resolution, weaning failure from inotropic therapy, or weaning from 
extracorporeal life support (ECLS) with a dose of 0.1–0.2 mcg/kg/min 
without a bolus, if systolic blood pressure is >100 mmHg with low 
dose vasopressors (noradrenaline <0.1 mcg/kg/min). Experimental 
and clinical studies also suggest an improvement of cardiac function 
with levosimendan in patients with septic shock.17,24
Evaluate Mechanical Support
In situations with increasing inotrope requirements or inadequate 
oxygen delivery despite high doses of inotropes, mechanic circulatory 
support must be evaluated.25 ECLS with an extracorporeal membrane 
oxygenator can be established quickly in experienced hands and offers 
an opportunity for temporary haemodynamic support.26 This might 
give time for decision-making (bridge to decision) or for the ventricle 
to recover (bridge to recovery). The ESC guidelines give IIb and IIa 
recommendations for short-term mechanical support as a bridge to 
decision and bridge to recovery, respectively.5 In patients with multiple 
organ dysfunctions mortality rates may be excessively high, prohibiting 
the use of ECLS in this particular patient population.27 Recently, the 
concept of awake ECLS has been introduced.28 The benefits of having 
patients on ECLS without mechanical ventilation include the possibility 
to assess the patients’ cognitive functions. It also allows interaction 
with the patient and the possibility to inquire his will, particularly in view 
of future therapeutic options (ventricular assist device, transplantation). 
As positive pressure ventilation and sedation can be avoided, patients 
awake on ECLS have a better haemodynamic stability. 
In selected patients with persisting cardiogenic shock under 
optimised pharmacologic therapy and/or weaning failure from ECLS, 
commercially available left- or biventricular assist devices (LVAD or 
BVAD) will provide sufficient organ perfusion for everyday life. These 
devices may be used in end-stage heart failure patients before heart 
transplantation (bridge to transplantation).26 Mechanical support will 
allow early rehabilitation leading to improved nutritional state, muscle 
strength and physical performance status. According to the ESC 
heart-failure guidelines, LVADs are a IIa indication for long-term use 
when transplantation is not possible (bridge to destination).5 
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Increased cardiac output by a LVAD may enlarge right ventricular 
(RV) volume load and cause RV-failure. Therefore, RV function must 
be assessed before considering the implantation of a LVAD.25 Surely 
the decision should be made in a multidisciplinary approach by 
experts due to the invasive nature of these devices. Complications 
may be related to the mandatory use of anticoagulation (bleeding, 
thromboembolism), mechanical shear stress on cellular blood 
components (haemolysis) and long-term infections of the implanted 
materials (drive line, cannulas, device).25,26,29–33 A summary of the 
advantages and risks of ECLS is provided in Table 2.
Control Heart Rate 
Adrenergic stress might induce inflammation and contribute to the 
pathogenesis of organ dysfunction.12,34 Hence, the use of beta-adrenergic 
drugs must be limited to a minimum. Taking this concept to the next 
level, the theoretical benefits of beta-blockers during critical illness 
have been discussed.35 Recently, Morelli et al. tested the effects of 
esmolol in septic patients.36 He included high-risk patients, who required 
noradrenaline and had a heart rate ≥95 beats per minute (BPM) despite 
24 hours of haemodynamic optimisation (MAP ≥65 mmHg, pulmonary 
artery occlusion pressure ≥ 12 mmHg, SvO2 ≥65 %). Esmolol was started 
at a dose of 0.5 mg/min and increased by 0.5–1.0 mg/min increments at 
20-minute intervals to an upper dose limit of 30 mg/min. The goal was 
a heart rate reduction to a rate between 80 to 94 BPM. If mixed venous 
oxygen saturation (SmvO2) decreased below 65 % and/or arterial 
lactate concentrations increased despite appropriate oxygenation 
(SaO2 ≥95 %) and a haemoglobin concentration ≥8 g/dl, levosimendan 
was administered at a dose of 0.05–0.2 mcg/kg/min for 24 hours. 
In their cohort study from 2013, the authors showed improvements 
in stroke volume, a decrease in norepinephrine requirement and a 
reduction of mortality.36 If these results are confirmed in future multi-
centre trials, this concept might revolutionise current practice in sepsis 
management. Potentially, this new concept might be usefully expanded 
to other critical ill patients with non-compensatory tachycardia.
A reduction in heart rate will allow a better ventricular filling in 
patients with diastolic myocardial dysfunction, resulting in an increase 
in stroke volume. The same is true for patients with supraventricular 
arrhythmias and atrial fibrillation (AF) with a high ventricular response 
rate.37 Additionally, a reduction in heart rate will reduce myocardial 
oxygen expenditure, hence inducing cardio-protection. However, some 
patients will have a high heart rate in order to compensate for a low 
stroke volume and/or an insufficient oxygen delivery. In these patients, 
prolonged heart rate reduction will result in haemodynamic collapse 
and eventually death. Hence, short-acting drugs should be used in 
patients in which it is unclear whether tachycardia is compensatory 
or not. In such situations, the authors use esmolol, a selective beta1-
blocker with a short half-life of 9 minutes, as an intravenous bolus 
(10–20 mg-wise up to 1 mg/kg), followed by a continuous infusion of 
0.05 mg/kg/min. The infusion rate can be increased every 30 minutes 
if needed. Of note, the negative inotropic effects of esmolol must be 
balanced against the potential benefits, and close haemodynamic 
monitoring including echocardiography is mandatory in unstable 
patients treated with beta-blockers.
Table 2: Advantages and Risks of Extracorporeal Life Support
ECLS Device Advantages Problems, Risks Comments, Recommendations References
Intra-aortic balloon • Left ventricular afterload- • Limb ischaemia • No benefit on 30-day mortality in 25,33,127 
 pump reduction • Infections patients with myocardial infarction 
 • 20 % decrease in wall tension • Bleeding complicated by cardiogenic shock 
 • Increase in coronary blood flow • Thrombo-embolic • No general recommendation for 
 (collateral flow) complications use in cardiogenic shock  
Extracorporeal • Emergency biventricular support • Peripheral cannulation: retrograde • 75 % survival rate for acute 26, 28, 29 
membrane • Temporary bridge flow, competing with normal myocarditis 
 oxygenation • Peripheral or central canulation blood flow • Overall survival to discharge: 58 % 
  • Difficult weaning 
  • Bleeding 
  • Thromboembolism 
  • Limb ischaemia  
  • Infections 
 Ventricular assist • Decompression of the left/right • Anticoagulation required • Selected patients with end-stage 25,26,32 
 device ventricle • Intra-cardiac shunts or aortic heart failure despite optimal 
 (left- or • Optimising organ-perfusion insufficiency prevent sufficient pharmacological treatment and  
bi-ventricular) • Bridge to transplantation decompression who are otherwise suitable 
 • Bridge to destination (one year • Right heart failure by increase for heart transplantation 
 survival 86 %)  in RV volume, loss of septal • Patients not suitable for heart 
  contribution to RV output, increase transplantation, but expected to 
  myocardial work; RV function must  survive >1 year with good functional 
  be assessed beforehand status (Class IIa; Level B) 
  • Drive line/cannula infection 
  • Bleeding 
  • Thromboembolism 
  • Haemolysis 
  • Arrhythmias 
  • Timing
RV = right ventricular
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Start Fluid Weaning
Fluid resuscitation is one of the corner stones of shock therapy to 
restore tissue perfusion.38 However, it was demonstrated that a liberal 
fluid regime increased mortality and morbidity in a diverse group 
of patients.39 Targeting a central venous pressure (CVP) between 
8–12 mmHg seemed to impair the microcirculation, was a risk factor 
for acute kidney injury (AKI) and increased mortality.39 The underlying 
mechanism seems to be a consecutive reduction in renal blood flow 
and glomerular filtration rate by a high venous pressure.39,40 Of note, 
there is no good correlation between CVP and fluid responsiveness41–43 
and therefore other preload variables should be used.44
Since fluid overload leads to increased morbidity in acute respiratory 
distress syndrome,45 pancreatitis46 and sepsis,47 the authors recommend 
a conservative fluid regime with fluids being administered preferably 
after assessing responsiveness.6 As soon as the patient has stabilised 
and noradrenaline requirements are below 10 mcg/min, fluid weaning 
is started. In haemodynamic stabile patients with AKI, protocolled renal 
replacement therapy (RRT) allows large negative fluid balances.48 Net fluid 
removal usually causes improvements in lung function, therefore leading 
to a reduction in ventilation days. Reduction of oedema in the bowel and 
the extremities will facilitate nutrition and mobilisation of the patient. 
Ventilate Safely
The authors use also the concept of lung-protective ventilation 
derived from acute respiratory distress syndrome (ARDS) patients for 
ICU patients with normal lungs. A tidal volume of ≤6 ml/kg should be 
chosen with plateau pressure of <30 mbar. Positive end-expiratory 
pressures (PEEP) are increased with increasing oxygen requirements. 
However, high PEEP levels increase RV afterload and might cause RV 
dysfunction.49 These heart-lung interactions might reduce RV stroke 
volume and consequently cardiac output, thereby decreasing oxygen 
delivery to the periphery. In case of further aggravation of hypoxaemia 
under increased PEEP, a persisting foramen ovale should be excluded. 
Hypercarbia causes pulmonary vasoconstriction and increases RV 
afterload, thus normoventilation should be targeted if possible in 
patients with pulmonary artery hypertension and/or RV dysfunction.
Another risk of invasive ventilation is ventilator associated pneumonia 
(VAP), which was defined by the following criteria during a time frame 
of 48 hours after intubation:50,51 
• new or progressive pulmonary infiltrates;
• fever; 
• leucocytosis;
• purulent secretion; 
• reduction of the PaO2:FiO2 ratio by ≥ 15 %.
In the American Thoracic Society definition from 2005, VAP is defined 
as pneumonia occuring 48–72 hours after intubation.52 However, 
diagnosis of VAP remains difficult as criteria are nonspecific and 
symptoms overlap as in conditions like sepsis, ARDS or atelectasis.50 
Radiographic signs are neither specific nor sensitive. In a study 
comparing chest X-ray findings in autopsy proven pneumonia, no 
sign had a diagnostic efficiency greater than 68 % and positive air 
bronchogramms predicted 65 % of pneumonias.53 Thus, a diagnosis of 
VAP is made by a combination of clinical signs, radiographic findings 
and, importantly, microbiological cultures.54,55
To reduce the incidence of VAP our hospital implemented the 
following bundle:56 
• Strict hand disinfection,
• oral hygiene with application of chlorhexidin, 
•  elevation of upper body >30° (if possible from a haemodynamic 
point of view),
• defined weaning and sedation protocols,
• continous subglottical suction,
• cuffpressure-control,
• daily reevaluation of gastric ulcer prophylaxis,
• Routine change of ventilator circuits and filters.
Manage Acute Renal Dysfunction
Understand Renal Dysfunction
Acute kidney injury (AKI) has a high incidence in patients after cardiac 
surgery varying between 1 and 30 %.57–61 The acute kidney injury network 
(AKIN) and risk, injury, failure, loss (RIFLE) criteria of AKI are accurate 
and early predictive of mortality with creatinine levels being the most 
useful marker.57,59,62,63 The pathophysiology is complex and involves 
pre-, intra- and post-operative risk factors.57,64 Most vulnerable is 
the patient with pre-existing renal dysfunction prior to surgery.57,59 
Nephrotoxins such as contrast agents and antibiotics, impaired 
cardiac output and poor renal perfusion, inflammation caused by 
surgical trauma, cardio-pulmonary-bypass and sepsis are further 
factors contributing to AKI.59,65 No preventive pharmacological therapy 
has been proven to be effective although studies indicate a possible 
benefit of statins pre-operatively.57,66–68 If possible, cardiac surgery 
should be performed ≥24 hours after coronary angiography to reduce 
the risk of AKI.69 Patients who need renal replacement therapy have a 
27 fold increased mortalitiy.70
Start Renal Replacement Therapy
The ideal time point of RRT-initiation remains unclear since the 
benefits of RRT must outweigh the risks of RRT61,71–74 In their cardio-
surgical ICU the authors start RRT with continuous veno-venous 
haemodialysis (CVVHD), if the patient has metabolic acidosis (pH <7.2), 
increasing potassium levels (>6.0 mmol/l), complications of azotaemia 
(blood urea >20 mmol/l) such as encephalopathy or fluid overload not 
responding to diuretics. 
The current Kidney Disease Improving Global Outcomes (KDIGO) 
guidelines recommend a dose of 20–25 ml/kg/hour of effluent flow in 
patients with AKI emphasising the need to individualise the patients 
dose by assessing volume status, acid-base status and electrolyte 
disturbances.62 Anticoagulation is required to prevent membrane 
clotting and dysfunction. Regional anticoagulation with citrate has the 
advantage over heparin75 to reduce the bleeding risk in post-operative 
patients after cardiac surgery, as heparin anticoagulation can be 
complicated by platelet- and red blood cell-consumption.75 However, 
impaired cellular aerobic metabolism (Krebs cycle) puts the patients 
at risk for insufficient citrate metabolism and citrate accumulation. In 
order to avoid this risk, the authors accept post-filter levels of calcium 
[ionised] as high as 0.5  mmol/l and limit the amount of citrate used 
(blood flow as low as 100 ml/minute, citrate concentration fix 3 mmol/l). 
The calcium quotient (total calcium [albumin corrected] divided by 
calcium [ionised] is measured daily. A value of ≥2.5 points to citrate 
accumulation and should prompt either a reduction of citrate load or a 
switch to alternative anticoagulation strategies. 
Interrupt Sedation Daily
After cardiac surgery most patients arrive in the ICU sedated and 
with some neuromuscular blockade. After resolving of neuromuscular 
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blockade sedation should keep the patient pain-free but interactive, 
calm but lucid and cooperative.76 Over-sedation was associated with 
prolonged mechanical ventilation and ICU-stay, while light sedation 
was associated with reduced length of ICU and hospital stay, less 
post-traumatic stress disorders and improved survival rates.76–78
In order to minimise sedation, the authors use short-acting sedative 
agents such as propofol or dexmedetomidine (if tolerated from a 
haemodynamic point of view). A non-benzodiazepine approach in 
critically ill patients led to a shorter duration of mechanical ventilation, 
a reduced length of ICU stay79 and a lower mortality80 compared to the 
use of benzodiazepines. The benefits of dexmedetomidine include 
the better sleep architecture,81 a lower risk of delirium and a shorter 
length of stay after cardiac surgery.82 When long-active sedatives such 
as midazolam must be used due to haemodynamic instability, daily 
interruption of sedation is mandatory, as this has been shown to 
reduce days on the ventilator, ICU length of stay and even mortality.78,83 
Detect and Treat Delirium
There is extensive evidence that delirium prolongs ICU stay84 and 
increases morbidity and mortality85–88 after cardiac surgery. Also a 
longer duration of delirium is associated with worse global cognition 
after discharge.89 Risk factors for delirium after cardiac surgery include 
age, preexisting cognitive impairment and cerebrovascular disease, 
benzodiazepine use and immobilsation.90 A review also pointed out 
that blood transfusion, mechanical ventilation and even use of intra-
aortic balloon pump91 are associated with increased risk of delirium. 
The confusion assessment method for the ICU (CAM-ICU)92,93 and the 
intensive care delirium screening checklist (ICDSC)94 are tools for the 
diagnosis of delirium in critically ill patients with reported pooled 
sensitivities and specificities of 80 % and 75 % for the ICDSC and 
76 % and 96 % for the CAM-ICU.95 Scarce data exist for the treatment 
of delirium.88 Cooperative patients with a hypoactive form of delirium 
and/or hallucinations are treated with haloperidol, preferably orally 
and with low doses. In the authors’ institution, agitated and non-
cooperative patients are treated primarily with enteral pipamperon, 
a mild neuroleptic agent with sedative properties. The drug is usually 
given in the afternoon and evening (e.g. 4pm, 6pm and 8pm) to treat 
agitation and to induce sleep. Intravenous dexmedetomidine is added 
in severely agitated patients. 
Rehabilitate Early
Prolonged critical illness results in loss of lean body mass and 
muscle weakness.96,97 Catecholamines induce myocyte apoptosis, 
and muscle weakness is potentially related to excessive sympathetic 
tone.12,98 Physiotherapy in the ICU is safe99 and can be started 
in cardiac surgery patients considering safety issues which are 
related to devices, sheaths or sternotomy.100 Early mobilisation and 
physiotherapy improves functional outcome and probably reduces 
length of ICU stay.101–103 Even in patients with ECLS, early physiotherapy 
and mobilisation is possible and safe.104,105
Feeding and Support Metabolism
Enteral Versus Parenteral Nutrition
Early enteral nutrition is recommended to preserve gastro-intestinal 
integrity and prevent bacterial translocation.106 On the other 
hand, enteral nutrition bears the risk of vomiting and aspiration, 
gastrointestinal obstruction and bowel ischaemia. This is particularly 
true during prolonged shock, when blood is redistributed from the gut 
to vital organs such as the brain and the heart. 
The authors start nutrition with 5 kcal/kg/day after shock resolution 
(normalised lactate levels, decreasing noradrenaline requirements) 
and increase stepwise to 25 kcal/kg/day over the next days. In 
patients without a contraindication for enteral nutrition, an early 
initiation of parenteral nutritision caused longer ICU stays and higher 
incidence of ICU aquired infections and higher health care costs.107 
Other complications such as poor glycaemic control were described 
with parenteral nutrition.108,109 Uncertainty exists in patients with 
contrandications for enteral feeding: a meta-analysis of older studies 
(between 1981 and 1994) showed an association with higher infection 
rates in patients with parenteral nutrition,110 whereas a newer study 
showed a shorter duration of mechanical ventilation (without effect 
on 60-day mortality) if patients received parenteral nutrition within 24 
hours of ICU admission.111 
Recently, a study showed benefits of parenteral nutrition was started 
on day four if enteral intake was <60  % of the targeted calories.112 
Therefore, the authors start parenteral nutrition between days four 
and eight if shock has resolved and enteral calory intake is <60 % of 
the targeted calories. As with enteral nutrition, parenteral nutrition is 
gradually established over days, up to 80 % of the target calory intake.
Stress Ulcer Prophylaxis
Following international guidelines, the authors recommend stress ulcer 
prophylaxis with proton pump inhibitors (e.g. entral or intravenous 
pantoprazole 40  mg once daily) in patients with risk factor of 
gastro-intestinal bleeding (coagulopathy or anticoagulation, prolonged 
mechanical ventilation >48 hours, hypotension, steroid therapy).113 
Meta analysis showed significantly less upper gastrointestinal bleeding 
with prophylaxis (in the absence of any mortality benefit).114–116 It is worth 
noting that stress ulcer prophylaxis is a grade 2C recommendation in 
the 2013 surviving sepsis campaign.113 Since there is an increased risk 
of pneumonia with increased stomach pH in ambulant patients,117 
there might be a greater incidence of VAP with use of stress ulcer 
prophylaxis. Clostridium difficile infections have also be associated 
with the use of prophylaxis.118 Taking these considerations into account, 
the use of stress ulcer prophylaxis should be limited to patients at risk 
of bleeding, until enteral nutrition is fully established.
Blood Glucose Control
Hyperglycaemia is common in patients with shock due to the 
physiological stress reaction. Excessive glucose plasma levels have 
been associated with adverse outcome.119,120 However, pharmacological 
glucose control bears the risk of hypoglycaemia.121 A large, international 
randomised trial showed that a liberal glucose management (targeting 
glucose levels <10 mmol/l) resulted in a lower mortality than 
targeting a glucose level of 4.5–6 mmol/l.122 As numerous arterial 
blood gas analyses including glucose measurements are performed, 
the authors have a low rate of accidental hypoglycemic episodes. In 
their ICU, the authors have agreed on blood glucose targets between 
4.5–8.5 mmol/l using continuous insulin infusions. 
Use DVT Prophylaxis
As critical ill patients are at risk for deep vein thrombosis (DVT),113,123 
prophylaxis is warranted. The decision when to start and how to 
provide DVT prophylaxis may be difficult as the bleeding risk is high 
after cardiac surgery. In a prospective multicentre trial independent 
predictors for major bleeding in patients receiving heparin thrombosis 
prophylaxis were described, including renal replacement therapy, low 
platelet count and antiplatelet agents during the past 7 days.124 
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